Nanjing Namemei secures RMB30m angel round

Nanjing Namemei announced that it has completed a 30 million yuan angel round of financing, with exclusive investment from the medical innovation fund managed by Oceanpine Healthcare Fund.

Nanjing Namemei announced that it has completed a 30 million yuan angel round of financing, with exclusive investment from the medical innovation fund managed by Oceanpine Healthcare Fund.

According to Sun Guoming, CEO of Nanjing Namemei, proceeds from this round of financing will be used to fund the joint development of the ferritin nano-enzyme delivery system with the Nano Enzyme Engineering Laboratory of the Chinese Academy of Sciences, the continued investment in clinical trial research, and the application for clinical approval of the ferritin nano-enzyme delivery system.

Established in early 2020, Nanjing Namemei is a high-tech enterprise engaged in the research and development of new ferritin nano-enzyme drug delivery system.

The company’s chairman and chief scientist is Yan Xiyun, an academician of the Chinese Academy of Sciences and president of the Asian Biophysics Association.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/16/nanjing-namemei-secures-rmb30m-angel-round/.

Leave a Reply

Please Login to Comment